Eli Lilly Beheer
Beheer criteriumcontroles 2/4
De CEO Eli Lilly is Dave Ricks, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 26.57M, bestaande uit 6.1% salaris en 93.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.067% van de aandelen van het bedrijf, ter waarde $ 455.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.2 jaar en 8.4 jaar.
Belangrijke informatie
Dave Ricks
Algemeen directeur
US$26.6m
Totale compensatie
| Percentage CEO-salaris | 6.1% |
| Dienstverband CEO | 7.8yrs |
| Eigendom CEO | 0.07% |
| Management gemiddelde ambtstermijn | 6.2yrs |
| Gemiddelde ambtstermijn bestuur | 8.4yrs |
Recente managementupdates
Recent updates
Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Aug 12Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
Aug 04Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Jul 25A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)
Jul 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$8b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$27m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$24m | US$1m | US$6b |
| Sep 30 2020 | n/a | n/a | US$6b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$6b |
| Dec 31 2019 | US$21m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$17m | US$1m | US$3b |
| Sep 30 2018 | n/a | n/a | US$372m |
| Jun 30 2018 | n/a | n/a | -US$166m |
| Mar 31 2018 | n/a | n/a | US$1b |
| Dec 31 2017 | US$16m | US$1m | -US$86m |
Compensatie versus markt: De totale vergoeding ($USD 26.57M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Dave is het afgelopen jaar met meer dan 20% gestegen.
CEO
Dave Ricks (56 yo)
7.8yrs
Tenure
US$26,565,732
Compensatie
Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 7.8yrs | US$26.57m | 0.067% $ 455.9m | |
| EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology | 6.4yrs | US$11.85m | 0.021% $ 145.8m | |
| Executive VP | 4.8yrs | US$7.01m | 0.0034% $ 22.9m | |
| Executive VP & President of Loxo | no data | US$4.89m | 0.0023% $ 15.5m | |
| Executive VP & CFO | less than a year | geen gegevens | 0.0012% $ 8.3m | |
| Senior VP of Finance & Chief Accounting Officer | 12yrs | geen gegevens | 0.00080% $ 5.4m | |
| EVP & Chief Information and Digital Officer | 3.5yrs | US$5.10m | 0.0012% $ 8.3m | |
| EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer | 3.4yrs | geen gegevens | 0.00088% $ 6.0m | |
| Executive Vice President of Human Resources & Diversity | 1.9yrs | geen gegevens | 0.00093% $ 6.3m | |
| Senior VP & President of Elanco Animal Health | 16.8yrs | US$5.38m | geen gegevens | |
| SVP of Global Active Pharmaceutical Ingredient | 8.3yrs | geen gegevens | geen gegevens | |
| EVP & President of Lilly Neuroscience | 6.2yrs | geen gegevens | 0.0073% $ 49.4m |
6.2yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van LLY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 7.8yrs | US$26.57m | 0.067% $ 455.9m | |
| Independent Director | 3.8yrs | US$335.50k | geen gegevens | |
| Chairman Emeritus | 15.8yrs | US$13.06m | geen gegevens | |
| Independent Director | 19yrs | US$344.88k | 0.000010% $ 67.8k | |
| Independent Director | 15.6yrs | US$336.00k | 0.000080% $ 542.7k | |
| Independent Director | 12.4yrs | US$349.15k | geen gegevens | |
| Independent Director | 2.5yrs | US$319.00k | 0.000040% $ 271.4k | |
| Lead Independent Director | 8.8yrs | US$373.00k | geen gegevens | |
| Independent Director | 12.9yrs | US$336.00k | geen gegevens | |
| Independent Director | 8.1yrs | US$345.00k | geen gegevens | |
| Independent Director | 5.9yrs | US$359.00k | geen gegevens | |
| Independent Director | 3.8yrs | US$316.00k | geen gegevens |
8.4yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van LLY wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).